NCT04766307 is a Phase 4 clinical trial of Interleukin-2 in Tuberculosis, Pulmonary, sponsored by Beijing Chest Hospital.

Who is sponsoring NCT04766307?

NCT04766307 is sponsored by Beijing Chest Hospital.

What drugs are being tested in NCT04766307?

Interventions in NCT04766307: Interleukin-2.

What condition does NCT04766307 study?

NCT04766307 studies Tuberculosis, Pulmonary.

Is NCT04766307 still recruiting?

NCT04766307 is currently status unknown. Last updated 23 February 2021.

Last reviewed 2021-02-23 · How we verify

NCT04766307

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2

Status unknown Phase 4 Last updated 23 February 2021

What this trial tests

Phase 4 trial testing Interleukin-2 in Tuberculosis, Pulmonary in 1,100 participants. Status unknown.

Timeline

20 July 2016

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Beijing Chest Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,100
Start date	20 July 2016
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	16 locations across China

Drugs / interventions tested

Interleukin-2

Conditions studied

Tuberculosis, Pulmonary — all drugs for Tuberculosis, Pulmonary →

Sponsor

Beijing Chest Hospital

Who can join

Adults 18 to 65, any sex, with Tuberculosis, Pulmonary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

<i>Mycobacterium tuberculosis</i>: immune response, biomarkers, and therapeutic intervention.
Zhuang L, Yang L, Li L, Ye Z, et al · · 2024 · cited 50× · PMID 38188605 · DOI 10.1002/mco2.419
The Research Progress in Immunotherapy of Tuberculosis.
Mi J, Liang Y, Liang J, Gong W, et al · · 2021 · cited 27× · PMID 34869066 · DOI 10.3389/fcimb.2021.763591
Advances in host-directed therapy for tuberculosis and HIV coinfection: enhancing immune responses.
Prasanna P, Herrera B, Schlesinger LS, Paiardini M, et al · · 2025 · cited 3× · PMID 40345900 · DOI 10.1016/j.tim.2025.04.006
Current and emerging therapies for pulmonary tuberculosis in adults.
Mahmood A, Ashfaq MB, Drain C, Melby E, et al · · 2026 · PMID 42046646 · DOI 10.1136/bmjmed-2025-001836

Verify or expand the search:

Other trials of Interleukin-2

Trials testing the same drug.

NCT06677710 — IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis · Phase 1 · suspended
NCT07288073 — TIL Therapy in cSCC and MCC · Phase 2 · recruiting
NCT06884670 — Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for L · Phase 2 · recruiting
NCT06598371 — A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 · Phase 1, PHASE2 · recruiting
NCT06640582 — TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas · Phase 1, PHASE2 · recruiting

Other recruiting trials for Tuberculosis, Pulmonary

Currently open trials in the same condition.

NCT07077213 — 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) in Tuberculosis Patients · recruiting
NCT07271225 — Safety and Efficacy of Ear Acupuncture for Antituberculosis Drug-Related Nausea and Vomiting · NA · recruiting
NCT06845618 — Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment · recruiting
NCT06253715 — Shortened Regimen for Drug-susceptible TB in Children · Phase 3 · recruiting
NCT06057519 — Pragmatic Optimized Rifampicin Trial · Phase 3 · recruiting

Other Beijing Chest Hospital trials

Trials by the same sponsor.

NCT07372781 — Clinical Study on the Early Bactericidal Activity of Contezolid Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
NCT07268664 — Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BLMZ Chinese Cohort · Phase 3 · not yet recruiting
NCT06809413 — Clinical Study on the Early Bactericidal Activity of Sitafloxacin Against Mycobacterium Abscessus Disease · Phase 2 · enrolling by invitation
NCT06764368 — Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors · Phase 2 · not yet recruiting
NCT06811025 — Phase II Clinical Study of Contezolid for the Treatment of Tuberculous Meningitis · Phase 1, PHASE2 · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04766307 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Chest Hospital
Last refreshed: 23 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04766307.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing